Last reviewed · How we verify
NCT05115877
Evaluation of Outcomes From Treatment of Benign or Malignant Gastrointestinal Diseases
trial in Gastrointestinal Disease in 1,000 participants. Status unknown.
17 May 2024
Quick facts
| Lead sponsor | Methodist Health System |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 7 January 2021 |
| Primary completion | 17 May 2024 |
| Estimated completion | 17 May 2024 |
| Sites | 1 location across United States |
Conditions studied
- Gastrointestinal Disease — all drugs for Gastrointestinal Disease →
Sponsor
Methodist Health System — full company profile →
Who can join
18 and older, any sex, with Gastrointestinal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be a retrospective, registry study collecting data of patients who were diagnosed with benign or malignant gastrointestinal diseases. Data will be collected from patient's chart retrospectively once the patients have completed proper treatment follow up with physicians' practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05115877
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Disease
Currently open trials in the same condition.
- NCT05053191 — Advancing Nursing Practices in Hospital Oncology Care · NA · active not recruiting
- NCT04949282 — Spanish Series of Patients Treated With the Radionuclide Lutetium177 · recruiting
- NCT03566160 — Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy · NA · active not recruiting
Other Methodist Health System trials
Trials by the same sponsor.
- NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
- NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
- NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
- NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
- NCT07492758 — Management of Extremity Injuries Registry · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05115877 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
- Last refreshed: 27 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05115877.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing